12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Company News  |  Deals

DBV, Centre d'Immunologie de Marseille-Luminy (CIML) deal

DBV partnered with the CIML to research the mechanism of action involved in DBV's epicutaneous immunotherapy (EPIT) method of treating allergies. The 18-month program will have three parts: study of cells involved in...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >